Celgene To Launch Pomalyst At $10,500 Per Treatment Cycle
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the immunomodulator Feb. 8 for multiple myeloma patients who have failed at least two prior therapies, including lenalidomide and bortezomib.